Survival Prognostic Factors of Male Breast Cancer Using Appropriate Survival Analysis for Small Sample Size: Three Center Experience
,
Abstract
Introduction: Breast cancer in men is a rare disease that has been increasing in recent decades. Identifying factors influencing the survival rate of these patients is particularly important considering the small sample size. The aim of this study was to present the results of the conventional Cox- LASSO method and compare it with the newer refined generalized log-rank (RGLR) method for analyzing survival data with a small sample size.
Methods: Available information related to men with breast cancer referred to 3 treatment centers in the country (Iran) between 2012 and 2020 were reviewed. Cox-LASSO and RGLR models were fitted on the data. The analyzes were done using R.4.1.2 software and the significance level of 0.05 was considered.
Results: About 60% of the conflicts are reported on the left side. About 53% of men have been diagnosed at a low stage. The tumor size of 75% of the patients was between 2 and 4.3. Most patients have received modified radical mastectomy (MRM) treatment and adjuvant radiotherapy. 80% of patients had received chemotherapy and most had received anthracycline-taxane base. According to Akaike's criterion, RGLR model (AIC=289.32) was better than Cox-LASSO (AIC=314.76) model. Results of RGLR model indicated that, age (p-value= 0.038, HR >50 vs <50 = 6.75, 95% CI: 2.70–17.30), left laterality (p-value = 0.019, HR left vs right = 3.45, 95% CI: 1.48–8.02), larger tumor size (p-value=0.033, HR T2 vs T1 = 3.70, 95% CI: 2.92–6.68; HR T3 vs T1= 4.34, 95% CI: 3.17–5.95), higher tumor grades (p-value<0.001, HR grade 2 or 3 vs grade1 = 8.67, 95% CI: 5.10–14.71), are influential factors decreasing male breast cancer patient’s survival.
Conclusion: Although the results of the two existing models in the field of small sample size survival analysis (Cox-LASSO and RGLR) are close to each other, the RGLR model has performed better than the Cox-LASSO. With smaller AIC and SE of parameter estimation, RGLR model was choose compared to Cox-LASSO model.
2. Longo DL, Giordano SH. Breast Cancer in Men. Longo DL, editor. NEJM. 2018 Jun 13;378(24):2311–20.
3. Aryannejad A, Saeedi Moghaddam S, Mashinchi B, Tabary M, Rezaei N, Shahin S, et al. National and subnational burden of female and male breast cancer and risk factors in Iran from 1990 to 2019: results from the Global Burden of Disease study 2019. Breast Cancer Res. 2023 Dec 1;25(1).
4. Chen Z, Xu L, Shi W, Zeng F, Zhuo R, Hao X, et al. Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–2017. Breast Cancer Res Treat. 2020 Apr 1;180(2):481–90.
5. Soni A, Paul D, Verma M, Kaur P, Chauhan A, Kaushal V. Male breast cancer: a budding and unaddressed issue. Oncol Clin Pract. 2023;19(3):158–66.
6. Wu J, Ren X, Yu Y, Yang J, Pan L, Zheng Q. Clinicopathological features and prognosis of male breast cancer. J Pract Oncol. 2020 Jul 7;35(6):517–23.
7. Constantinou N, Marshall C, Marshall
H. Discussion and Optimization of the Male Breast Cancer Patient Experience. Vol. 5, Journal of Breast Imaging. Oxford Academic; 2023. p. 339–45.
8. Yao N, Shi W, Liu T, Siyin ST, Wang W, Duan N, et al. Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer. Sci Rep. 2022;12(1).
9. In J, Lee D. Survival analysis: part II- applied clinical data analysis. Korean J Anesth. 2019;72(5):441–57.
10. Tibshirani R. The lasso method for variable selection in the cox model. Stat Med. 1997;16(4):385–95.
11. Xu R, Shaw PA, Mehrotra D V. Hazard Ratio Estimation in Small Samples. Stat Biopharm Res. 2018 Apr 3;10(2):139–49.
12. Shahraki HR, Salehi A, Zare N. Survival prognostic factors of male breast cancer in Southern Iran: A LASSO-Cox regression approach. Asian Pacific J Cancer Prev. 2015;16(15):6773–7.
13. Salehi A, Zeraati H, Mohammad K, Mahmoudi M, Talei AR, Ghaderi A, et al. Survival of male breast cancer in fars, South of Iran. Iran Red Crescent Med J. 2011 Feb;13(2):99–105.
14. N Yao, W Shi, T Liu, ST Siyin, W Wang, N Duan, G Xu JQ. Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer. Sci Rep. 2022;12(1):220.
15. Ginsburg O, Yip CH, Brooks A, Cabanes A, Caleffi M, Yataco JAD, et al. Breast Cancer Early Detection: A Phased Approach to Implementation. Cancer. 2020;126(S10):2379–93.
16. Zahra AZ, Kadkhoda S, Behjati F, Moghaddam FA, Badiei A, Sirati F, et al. Mutation Screening of BRCA Genes in 10 Iranian Males with Breast Cancer. Int J Mol Cell Med. 2016;5(2):114.
17. Ottini L, Palli D, Rizzo S, Federico M, Bazan V, Russo A. Male breast cancer. Crit Rev Oncol Hematol. 2010 Feb 1;73(2):141–55.
| Files | ||
| Issue | Vol 9 No 3 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jbe.v9i3.15451 | |
| Keywords | ||
| LASSO Male breast cancer Prognosis; RGLR Risk factors Survival analysis Small sample size | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
